Moderna's mRNA Vaccine Shows Superior Mpox Protection in Animal Studies

New research indicates Moderna's mRNA-1769 vaccine outperforms existing options in reducing symptoms and transmission.

Moderna's mRNA-1769 vaccine demonstrated fewer lesions and shorter disease duration in primates compared to the MVA vaccine.
The mRNA vaccine elicited a stronger immune response with higher and more diverse antibody production.
All vaccinated primates survived a lethal mpox strain, whereas most unvaccinated controls did not.
The mRNA vaccine also showed potential cross-immunity to other Orthopoxviruses.
Moderna's mRNA-1769 is currently in early-stage human trials to assess safety and immune response.